Skip to main content

Table 3 Regression analyses comparing the impact of antiretroviral therapy components on biomarker changes

From: Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study

   Univariable Multivariable*
Marker Antiretrovirals Mean fold change percentage difference (95% CI) P value Mean fold change percentage difference (95% CI) P value
IL-6 TDF/FTC Ref.    
ABC/3TC 1 (-67 to 41) 0.97 4 (-80 to 49) 0.90
EFV Ref.    
ATV/r -39 (-120 to 12) 0.16 -20 (-101 to 28) 0.48
LPV/r 38 (-8 to 63) 0.09 43 (-23 to 74) 0.15
hs-CRP TDF/FTC Ref.    
ABC/3TC 18 (-77 to 62) 0.60 7 (-155 to 66) 0.88
EFV Ref.    
ATV/r -16 (-139 to 43) 0.68 -34 (-203 to 41) 0.47
LPV/r 16 (-97 to 63) 0.67 41 (-29 to 82) 0.39
sCD14 TDF/FTC Ref.    
ABC/3TC 7 (-13 to 3) 0.48 14 (-8 to 31) 0.18
EFV Ref.    
ATV/r -14 (-36 to 4) 0.13 -19 (-43 to 1) 0.06
LPV/r -6 (-31 to 14) 0.57 -4 (-36 to 21) 0.77
IP10 TDF/FTC Ref.    
ABC/3TC 16 (-22 to 42) 0.36 30 (-6 to 54) 0.09
EFV Ref.    
ATV/r -55 (-118 to -12) 0.01 -57 (-120 to -11) 0.011
LPV/r -26 (-92 to 17) 0.27 -4 (-80 to 39) 0.87
MIG TDF/FTC Ref.    
ABC/3TC -8 (-103 to 42) 0.80 24 (-62 to 65) 0.47
EFV Ref.    
ATV/r -146 (-306 to -45) 0.001 -136 (-339 to -27) 0.007
  LPV/r -151 (-395 to -31) 0.006 -48 (-297 to 45) 0.44
  1. TDF, Tenofovir; FTC, Emtricitabine; ABC, Abacavir; 3TC, lamivudine; EFV, Efavirenz; ATV/r, Atazanavir/ritonavir; LPV/r, Lopinavir/ritonavir; IL6, Interleukin-6; hs-CRP, Highly-sensitive C-reactive protein; sCD14, soluble CD14; 1P10, Interferon-γ-inducible protein 10; MIG, Monokine induced by interferon-γ; CI, Confidence Interval.
  2. *Adjusted for age, smoking, prior AIDS, baseline CD4 cell count, baseline HIV viral load, HCV or HBV coinfection, and viral blips.
\